Nektar Q3 net loss narrows to $37.1M; sells Huntsville business for $90M

NEKTAR THERAPEUTICS

Net loss $37.1M ($0.18/sh) vs $45.8M ($0.24) in Q3 2023; revenue flat at $24.1M.
Cash & investments $249M as of Sep 30; expected to fund operations into Q4 2026.
Definitive agreement to sell Huntsville PEGylation business to Ampersand for $90M ($70M cash + $20M equity).
R&D expense rose to $35.0M from $24.1M, driven by rezpegaldesleukin and NKTR-0165 development.
Topline data for rezpegaldesleukin Phase 2b in atopic dermatitis expected H1 2025; alopecia areata H2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.